RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $345
RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $350 to $345.
Stocks · News reference
Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views
US stocks gain, Dow up 300 points as tech shares surge 5.3%, Bristol-Myers Squibb beats expectations, Columbus McKinnon and Xerox report strong earnings.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average
The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.
Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight
The type 2 diabetes market is projected to experience steady growth through 2036, driven by rising global prevalence, obesity, and adoption of next-generation therapies including GLP-1 receptor agonists and SGLT2 inhibitors. Key emerging drugs from major pharmaceutical companies like Novo Nordisk, Eli Lilly, and Boehringer Ingelheim are expected to reshape the market landscape with improved glycemic control and weight management benefits.
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Alnylam Pharmaceuticals faces a securities fraud investigation following a significant stock price decline. On July 30, 2026, the company lowered its TTR product sales guidance by approximately $200 million due to slower-than-expected market adoption in the ATTR-CM market after initial pent-up demand was satisfied. The announcement triggered a 28.31% stock price drop, prompting a class action investigation by Glancy Prongay Wolke & Rotter LLP on behalf of affected shareholders.
Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%
Bristol Myers Squibb reports positive Phase 3 trial data, showing ZENBEXUS cuts the multiple myeloma progression risk by 51%.
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, as an independent board director, bringing over 25 years of clinical development and regulatory expertise from companies including MyoKardia, Genentech/Roche, Alumis, and Abivax. Zhang will support Aardvark's regulatory strategy for ARD-101, its lead candidate for Prader-Willi Syndrome treatment, at a critical juncture following an FDA clinical hold.